Atropine Sulfate Cooper may be available in the countries listed below.
Atropine sulfate (a derivative of Atropine) is reported as an ingredient of Atropine Sulfate Cooper in the following countries:
International Drug Name Search
Antotalgin may be available in the countries listed below.
Phenazone is reported as an ingredient of Antotalgin in the following countries:
International Drug Name Search
Anti-Uron may be available in the countries listed below.
Mesna is reported as an ingredient of Anti-Uron in the following countries:
International Drug Name Search
Lanzoprazol may be available in the countries listed below.
Lansoprazole is reported as an ingredient of Lanzoprazol in the following countries:
International Drug Name Search
Diatol may be available in the countries listed below.
Tolbutamide is reported as an ingredient of Diatol in the following countries:
International Drug Name Search
Peracef may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Cefoperazone is reported as an ingredient of Peracef in the following countries:
International Drug Name Search
Anbinex may be available in the countries listed below.
Antithrombin III is reported as an ingredient of Anbinex in the following countries:
International Drug Name Search
Bicarbonato Sod Bieffe M may be available in the countries listed below.
Sodium Bicarbonate is reported as an ingredient of Bicarbonato Sod Bieffe M in the following countries:
International Drug Name Search
Naproxen Hexal may be available in the countries listed below.
Naproxen is reported as an ingredient of Naproxen Hexal in the following countries:
International Drug Name Search
Papaverina ritardo Hè Teofarma may be available in the countries listed below.
Papaverine hydrochloride (a derivative of Papaverine) is reported as an ingredient of Papaverina ritardo Hè Teofarma in the following countries:
International Drug Name Search
Scantropil may be available in the countries listed below.
Piracetam is reported as an ingredient of Scantropil in the following countries:
International Drug Name Search
Azo Uroflam may be available in the countries listed below.
Norfloxacin is reported as an ingredient of Azo Uroflam in the following countries:
International Drug Name Search
Ganticol may be available in the countries listed below.
Sulfafurazole is reported as an ingredient of Ganticol in the following countries:
International Drug Name Search
Adco-Lamivudine may be available in the countries listed below.
Lamivudine is reported as an ingredient of Adco-Lamivudine in the following countries:
International Drug Name Search
Antalyre may be available in the countries listed below.
Acetylsalicylic Acid is reported as an ingredient of Antalyre in the following countries:
International Drug Name Search
Derm-Aid may be available in the countries listed below.
Hydrocortisone is reported as an ingredient of Derm-Aid in the following countries:
International Drug Name Search
Lactecon may be available in the countries listed below.
Lactulose is reported as an ingredient of Lactecon in the following countries:
International Drug Name Search
Spazmotek may be available in the countries listed below.
Scopolamine butylbromide (a derivative of Scopolamine) is reported as an ingredient of Spazmotek in the following countries:
International Drug Name Search
Sandoz Furosemide may be available in the countries listed below.
Furosemide is reported as an ingredient of Sandoz Furosemide in the following countries:
International Drug Name Search
In the US, Tylenol with Codeine (acetaminophen/codeine systemic) is a member of the drug class narcotic analgesic combinations and is used to treat Cough, Osteoarthritis and Pain.
US matches:
Codeine phosphate hemihydrate (a derivative of Codeine) is reported as an ingredient of Tylenol with Codeine in the following countries:
Paracetamol is reported as an ingredient of Tylenol with Codeine in the following countries:
International Drug Name Search
Minoxidil is reported as an ingredient of Men's Rogaine in the following countries:
International Drug Name Search
Dactiran may be available in the countries listed below.
Piperidolate hydrochloride (a derivative of Piperidolate) is reported as an ingredient of Dactiran in the following countries:
International Drug Name Search
Vowlo may be available in the countries listed below.
Sodium Gualenate is reported as an ingredient of Vowlo in the following countries:
International Drug Name Search
Droptimol may be available in the countries listed below.
Timolol maleate (a derivative of Timolol) is reported as an ingredient of Droptimol in the following countries:
International Drug Name Search
Clever may be available in the countries listed below.
Ebastine is reported as an ingredient of Clever in the following countries:
International Drug Name Search
Delcopan may be available in the countries listed below.
Dextromethorphan is reported as an ingredient of Delcopan in the following countries:
International Drug Name Search
Loram may be available in the countries listed below.
Loratadine is reported as an ingredient of Loram in the following countries:
Lorazepam is reported as an ingredient of Loram in the following countries:
International Drug Name Search
Calcium Carbonate is reported as an ingredient of Calci-Mix in the following countries:
International Drug Name Search
Nardelzine may be available in the countries listed below.
Phenelzine sulfate (a derivative of Phenelzine) is reported as an ingredient of Nardelzine in the following countries:
International Drug Name Search
Macox may be available in the countries listed below.
Ethambutol dihydrochloride (a derivative of Ethambutol) is reported as an ingredient of Macox in the following countries:
Rifamycin is reported as an ingredient of Macox in the following countries:
International Drug Name Search
Busol may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Buserelin acetate (a derivative of Buserelin) is reported as an ingredient of Busol in the following countries:
International Drug Name Search
Géméprost may be available in the countries listed below.
Géméprost (DCF) is also known as Gemeprost (Rec.INN)
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Notis may be available in the countries listed below.
Omeprazole is reported as an ingredient of Notis in the following countries:
International Drug Name Search
Deflamat may be available in the countries listed below.
Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Deflamat in the following countries:
International Drug Name Search
Prodoner may be available in the countries listed below.
Beraprost sodium (a derivative of Beraprost) is reported as an ingredient of Prodoner in the following countries:
International Drug Name Search
Stilla Decongestionante may be available in the countries listed below.
Tetryzoline hydrochloride (a derivative of Tetryzoline) is reported as an ingredient of Stilla Decongestionante in the following countries:
International Drug Name Search
Choriomon may be available in the countries listed below.
Chorionic Gonadotrophin is reported as an ingredient of Choriomon in the following countries:
International Drug Name Search
X-Trant may be available in the countries listed below.
Estramustine 17ß-(disodium phosphate) (a derivative of Estramustine) is reported as an ingredient of X-Trant in the following countries:
International Drug Name Search
Colchicina L.CH. may be available in the countries listed below.
Colchicine is reported as an ingredient of Colchicina L.CH. in the following countries:
International Drug Name Search
Finastéride Ranbaxy may be available in the countries listed below.
Finasteride is reported as an ingredient of Finastéride Ranbaxy in the following countries:
International Drug Name Search
Histergan may be available in the countries listed below.
Diphenhydramine hydrochloride (a derivative of Diphenhydramine) is reported as an ingredient of Histergan in the following countries:
International Drug Name Search
Prostandril may be available in the countries listed below.
Flutamide is reported as an ingredient of Prostandril in the following countries:
International Drug Name Search
Vicks Husten-Löser may be available in the countries listed below.
Guaifenesin is reported as an ingredient of Vicks Husten-Löser in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Lufenuron is reported as an ingredient of Program in the following countries:
Nitenpyram is reported as an ingredient of Program in the following countries:
International Drug Name Search
Moditen Depot may be available in the countries listed below.
Fluphenazine decanoate (a derivative of Fluphenazine) is reported as an ingredient of Moditen Depot in the following countries:
International Drug Name Search
Cutisone may be available in the countries listed below.
Fluticasone propionate (a derivative of Fluticasone) is reported as an ingredient of Cutisone in the following countries:
International Drug Name Search
Gliserin-Kansuk-K may be available in the countries listed below.
Glycerol is reported as an ingredient of Gliserin-Kansuk-K in the following countries:
International Drug Name Search
U-Oscine may be available in the countries listed below.
Scopolamine butylbromide (a derivative of Scopolamine) is reported as an ingredient of U-Oscine in the following countries:
International Drug Name Search
Torgyl may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Metronidazole is reported as an ingredient of Torgyl in the following countries:
International Drug Name Search
Metformin Generichealth may be available in the countries listed below.
Metformin hydrochloride (a derivative of Metformin) is reported as an ingredient of Metformin Generichealth in the following countries:
International Drug Name Search
Nitroxolin may be available in the countries listed below.
Nitroxoline is reported as an ingredient of Nitroxolin in the following countries:
International Drug Name Search
Orap forte may be available in the countries listed below.
Pimozide is reported as an ingredient of Orap forte in the following countries:
International Drug Name Search
Nebispes may be available in the countries listed below.
Nebivolol is reported as an ingredient of Nebispes in the following countries:
International Drug Name Search
Amiodarona MK may be available in the countries listed below.
Amiodarone is reported as an ingredient of Amiodarona MK in the following countries:
International Drug Name Search
CIV
For Intravenous Use in Adults
For Rectal and Intramuscular Use Only in Pediatric Patients
Brevital should be used only in hospital or ambulatory care settings that provide for continuous monitoring of respiratory (e.g. pulse oximetry) and cardiac function. Immediate availability of resuscitative drugs and age- and size-appropriate equipment for bag/valve/mask ventilation and intubation and personnel trained in their use and skilled in airway management should be assured. For deeply sedated patients, a designated individual other than the practitioner performing the procedure should be present to continuously monitor the patient. (See WARNINGS)
Brevital® Sodium (Methohexital Sodium for Injection, USP) is 2,4,6 (1H, 3H, 5H)-Pyrimidinetrione, 1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-, (±)-, monosodium salt and has the empirical formula C14H17N2NaO3. Its molecular weight is 284.29.
The structural formula is as follows:
Methohexital sodium is a rapid, ultrashort-acting barbiturate anesthetic. Methohexital sodium for injection is a freeze-dried, sterile, nonpyrogenic mixture of methohexital sodium with 6% anhydrous sodium carbonate added as a buffer. It contains not less than 90% and not more than 110% of the labeled amount of methohexital sodium. It occurs as a white, freeze-dried plug that is freely soluble in water.
This product is oxygen sensitive. The pH of the 1% solution is between 10 and 11; the pH of the 0.2% solution in 5% dextrose is between 9.5 and 10.5.
Methohexital sodium may be administered by direct intravenous injection or continuous intravenous drip, intramuscular or rectal routes (see PRECAUTIONS—Pediatric Use). Reconstituting instructions vary depending on the route of administration (see DOSAGE AND ADMINISTRATION).
Compared with thiamylal and thiopental, methohexital is at least twice as potent on a weight basis, and its duration of action is only about half as long. Although the metabolic fate of methohexital in the body is not clear, the drug does not appear to concentrate in fat depots to the extent that other barbiturate anesthetics do. Thus, cumulative effects are fewer and recovery is more rapid with methohexital than with thiobarbiturates. In experimental animals, the drug cannot be detected in the blood 24 hours after administration.
Methohexital differs chemically from the established barbiturate anesthetics in that it contains no sulfur. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.
Intravenous administration of methohexital results in rapid uptake by the brain (within 30 seconds) and rapid induction of sleep.
Following intramuscular administration to pediatric patients, the onset of sleep occurs in 2 to 10 minutes. A plasma concentration of 3 µg/mL was achieved in pediatric patients 15 minutes after an intramuscular dose (10 mg/kg) of a 5% solution. Following rectal administration to pediatric patients, the onset of sleep occurs in 5 to 15 minutes. Plasma methohexital concentrations achieved following rectal administration tend to increase both with dose and with the use of more dilute solution concentrations when using the same dose. A 25 mg/kg dose of a 1% methohexital solution yielded plasma concentrations of 6.9 to 7.9 µg/mL 15 minutes after dosing. The absolute bioavailability of rectal methohexital sodium is 17%.
With single doses, the rate of redistribution determines duration of pharmacologic effect. Metabolism occurs in the liver through demethylation and oxidation. Side-chain oxidation is the most important biotransformation involved in termination of biologic activity. Excretion occurs via the kidneys through glomerular filtration.
Brevital Sodium can be used in adults as follows:
Brevital Sodium can be used in pediatric patients older than 1 month as follows:
Brevital Sodium is contraindicated in patients in whom general anesthesia is contraindicated, in those with latent or manifest porphyria, or in patients with a known hypersensitivity to barbiturates.
See boxed Warning.
As with all potent anesthetic agents and adjuncts, Brevital should be used only in hospital or ambulatory care settings that provide for continuous monitoring of respiratory (e.g. pulse oximetry) and cardiac function. Immediate availability of resuscitative drugs and age- and size-appropriate equipment for bag/valve/mask ventilation and intubation and personnel trained in their use and skilled in airway management should be assured. For deeply sedated patients, a designated individual other than the practitioner performing the procedure should be present to continuously monitor the patient.
Maintenance of a patent airway and adequacy of ventilation must be ensured during induction and maintenance of anesthesia with methohexital sodium solution. Laryngospasm is common during induction with all barbiturates and may be due to a combination of secretions and accentuated reflexes following induction or may result from painful stimuli during light anesthesia. Apnea/hypoventilation may be noted during induction, which may impair pulmonary ventilation; the duration of apnea may be longer than that produced by other barbiturate anesthetics. Cardiorespiratory arrest may occur.
This prescribing information describes intravenous use of methohexital sodium in adults. It also discusses intramuscular and rectal administration in pediatric patients older than one month. Although the published literature discusses intravenous administration in pediatric patients, the safety and effectiveness of intravenous administration of methohexital sodium in pediatric patients have not been established in well-controlled, prospective studies. (See PRECAUTIONS— Pediatric Use)
Seizures may be elicited in subjects with a previous history of convulsive activity, especially partial seizure disorders.
Because the liver is involved in demethylation and oxidation of methohexital and because barbiturates may enhance preexisting circulatory depression, severe hepatic dysfunction, severe cardiovascular instability, or a shock-like condition may be reason for selecting another induction agent.
Prolonged administration may result in cumulative effects, including extended somnolence, protracted unconsciousness, and respiratory and cardiovascular depression. Respiratory depression in the presence of an impaired airway may lead to hypoxia, cardiac arrest, and death.
The CNS-depressant effect of Brevital Sodium may be additive with that of other CNS depressants, including ethyl alcohol and propylene glycol.
Unintended intra-arterial injection of barbiturate solutions may be followed by the production of platelet aggregates and thrombosis, starting in arterioles distal to the site of injection. The resulting necrosis may lead to gangrene, which may require amputation. The first sign in conscious patients may be a complaint of fiery burning that roughly follows the distribution path of the injected artery; if noted, the injection should be stopped immediately and the situation reevaluated. Transient blanching may or may not be noted very early; blotchy cyanosis and dark discoloration may then be the first sign in anesthetized patients. There is no established treatment other than prevention. The following should be considered prior to injection:
Postinjury arterial injection of vasodilators and/or arterial infusion of parenteral fluids are generally regarded to be of no value in altering outcome. Animal experiments and published individual case reports concerned with a variety of arteriolar irritants, including barbiturates, suggest that 1 or more of the following may be of benefit in reducing the area of necrosis:
If extravasation is noted during injection of methohexital, the injection should be discontinued until the situation is remedied. Local irritation may result from extravasation; subcutaneous swelling may also serve as a sign of arterial or periarterial placement of the catheter.
All routes of administration of Brevital Sodium are often associated with hiccups, coughing, and/or muscle twitching, which may also impair pulmonary ventilation. Following induction, temporary hypotension and tachycardia may occur.
Recovery from methohexital anesthesia is rapid and smooth. The incidence of postoperative nausea and vomiting is low if the drug is administered to fasting patients. Postanesthetic shivering has occurred in a few instances.
The usual precautions taken with any barbiturate anesthetic should be observed with Brevital Sodium. The drug should be used with caution in patients with asthma, obstructive pulmonary disease, severe hypertension or hypotension, myocardial disease, congestive heart failure, severe anemia, or extreme obesity.
Methohexital sodium should be used with extreme caution in patients in status asthmaticus. Caution should be exercised in debilitated patients or in those with impaired function of respiratory, circulatory, renal, hepatic, or endocrine systems.
When appropriate, patients should be instructed as to the hazards of drowsiness that may follow use of Brevital Sodium. Outpatients should be released in the company of another individual, and no skilled activities, such as operating machinery or driving a motor vehicle, should be engaged in for 8 to 12 hours.
BSP and liver function studies may be influenced by administration of a single dose of barbiturates.
Prior chronic administration of barbiturates or phenytoin (e.g. for seizure disorder) appears to reduce the effectiveness of Brevital Sodium. Barbiturates may influence the metabolism of other concomitantly used drugs, such as phenytoin, halothane, anticoagulants, corticosteroids, ethyl alcohol, and propylene glycol-containing solutions.
Studies in animals to evaluate the carcinogenic and mutagenic potential of Brevital Sodium have not been conducted. Reproduction studies in animals have revealed no evidence of impaired fertility.
Reproduction studies have been performed in rabbits and rats at doses up to 4 and 7 times the human dose respectively and have revealed no evidence of harm to the fetus due to methohexital sodium. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Brevital Sodium has been used in cesarean section delivery but, because of its solubility and lack of protein binding, it readily and rapidly traverses the placenta.
Caution should be exercised when Brevital Sodium is administered to a nursing woman.
The safety and effectiveness of methohexital sodium in pediatric patients below the age of 1 month have not been established. Seizures may be elicited in subjects with a previous history of convulsive activity, especially partial seizure disorders. Apnea has been reported following dosing with methohexital regardless of the route of administration used. Studies using methohexital sodium intravenously in pediatric patients have been reported in the published literature. This literature is not adequate to establish the safety and effectiveness of intravenous administration of methohexital sodium in pediatric patients. Due to a variety of limitations such as study design, biopharmaceutic issues, and the wide range of effects observed with similar doses of intravenous methohexital, additional studies of intravenous methohexital in pediatric patients are necessary before this route can be recommended in pediatric patients. (See WARNINGS)
Clinical studies of Brevital did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. Elderly subjects may commonly have conditions in which methohexital should be used cautiously such as obstructive pulmonary disease, severe hypertension or hypotension, preexisting circulatory depression, myocardial disease, congestive heart failure, or severe anemia. Caution should be exercised in debilitated patients or in those with impaired function of respiratory, circulatory, renal, hepatic, or endocrine systems (see WARNINGS, PRECAUTIONS and ADVERSE REACTIONS). Barbiturates may influence the metabolism of other concomitantly used drugs that are commonly taken by the elderly, such as anticoagulants and corticosteroids. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see PRECAUTIONS-Drug Interactions).
Side effects associated with Brevital Sodium are extensions of pharmacologic effects and include:
Cardiovascular—Circulatory depression, thrombophlebitis, hypotension, tachycardia, peripheral vascular collapse, and convulsions in association with cardiorespiratory arrest
Respiratory—Respiratory depression (including apnea), cardiorespiratory arrest, laryngospasm, bronchospasm, hiccups, and dyspnea
Neurologic—Skeletal muscle hyperactivity (twitching), injury to nerves adjacent to injection site, and seizures
Psychiatric—Emergence delirium, restlessness, and anxiety may occur, especially in the presence of postoperative pain
Gastrointestinal—Nausea, emesis, abdominal pain, and liver function tests abnormal
Allergic—Erythema, pruritus, urticaria, and cases of anaphylaxis have been reported rarely
Other—Other adverse reactions include pain at injection site, salivation, headache, and rhinitis
For medical advice about adverse reactions contact your medical professional. To report SUSPECTED ADVERSE REACTIONS, contact JHP at 1-866-923-2547 or MEDWATCH at 1-800-FDA-1088 (1-800-332-1088) or http://www.fda.gov/medwatch/.
Brevital Sodium is a Schedule IV drug.
Brevital Sodium may be habit-forming.
The onset of toxicity following an overdose of intravenously administered methohexital will be within seconds of the infusion. If methohexital is administered rectally or is ingested, the onset of toxicity may be delayed. The manifestations of an ultrashort-acting barbiturate in overdose include central nervous system depression, respiratory depression, hypotension, loss of peripheral vascular resistance, and muscular hyperactivity ranging from twitching to convulsive-like movements. Other findings may include convulsions and allergic reactions. Following massive exposure to any barbiturate, pulmonary edema, circulatory collapse with loss of peripheral vascular tone, and cardiac arrest may occur.
To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the Physicians' Desk Reference (PDR). In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in your patient.
Establish an airway and ensure oxygenation and ventilation. Resuscitative measures should be initiated promptly. For hypotension, intravenous fluids should be administered and the patient's legs raised. If desirable increase in blood pressure is not obtained, vasopressor and/or inotropic drugs may be used as dictated by the clinical situation.
For convulsions, diazepam intravenously and phenytoin may be required. If the seizures are refractory to diazepam and phenytoin, general anesthesia and paralysis with a neuromuscular blocking agent may be necessary.
Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than emesis or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient's airway when employing gastric emptying or charcoal.
Facilities for assisting ventilation and administering oxygen are necessary adjuncts for all routes of administration of anesthesia. Since cardiorespiratory arrest may occur, patients should be observed carefully during and after use of Brevital Sodium. Age- and size-appropriate resuscitative equipment (ie, intubation and cardioversion equipment, oxygen, suction, and a secure intravenous line) and personnel qualified in its use must be immediately available.
Preanesthetic medication is generally advisable. Brevital Sodium may be used with any of the recognized preanesthetic medications.
FOLLOW DILUTING INSTRUCTIONS EXACTLY.
Solutions of Brevital Sodium should be freshly prepared and used promptly. Reconstituted solutions of Brevital Sodium are chemically stable at room temperature for 24 hours.
DO NOT USE DILUENTS CONTAINING BACTERIOSTATS.
Preferred diluent: Sterile Water for Injection
Acceptable diluents: 5% Dextrose Injection (for IV or rectal administration only), 0.9% Sodium Chloride Injection
Incompatible diluents: Lactated Ringer's Injection
1% solutions (10 mg/mL) should be prepared for intravenous use. Contents of vials should be diluted as follows:
| Strength | Amount of Diluent to Be Added to the Contents of the Vial | For 1% methohexital solution |
|---|---|---|
| 500 mg | 50 mL | no further dilution needed |
| 2.5 g | 15 mL | add to 235 mL for 250 mL total volume |
When the first dilution is made with the 2.5 g, the solution in the vial will be yellow. When further diluted to make a 1% solution, it must be clear and colorless or should not be used. For continuous drip anesthesia, prepare a 0.2% solution by adding 500 mg of Brevital Sodium to 250 mL of diluent. For this dilution, either 5% glucose solution or isotonic (0.9%) sodium chloride solution is recommended instead of distilled water in order to avoid extreme hypotonicity.
For intramuscular administration, contents of the vials should be diluted as follows:
| Strength | Amount of Diluent* to Be Added to the Contents of the Vial | Methohexital Concentration after Dilution |
|---|---|---|
| ||
| 500 mg vial | 10 mL | 5% Solution (50 mg/mL) |
| 2.5 g vial | 50 mL | 5% Solution (50 mg/mL) |
For rectal administration, contents of the vials should be diluted as follows:
| Strength | Amount of Diluent to Be Added to the Contents of the Vial | Methohexital Concentration after Dilution |
|---|---|---|
| 500 mg vial | 50 mL | 1% Solution (10 mg/mL) |
| 2.5 g vial (larger vial needed) | 250 mL | 1% Solution (10 mg/mL) |
Dosage is highly individualized; the drug should be administered only by those completely familiar with its quantitative differences from other barbiturate anesthetics.
Brevital Sodium is administered intravenously in a concentration of no higher than 1%. Higher concentrations markedly increase the incidence of muscular movements and irregularities in respiration and blood pressure.
For induction of anesthesia, a 1% solution is administered at a rate of about 1 mL/5 seconds. Gaseous anesthetics and/or skeletal muscle relaxants may be administered concomitantly. The dose required for induction may range from 50 to 120 mg or more but averages about 70 mg. The usual dosage in adults ranges from 1 to 1.5 mg/kg. The induction dose usually provides anesthesia for 5 to 7 minutes.
Maintenance of anesthesia may be accomplished by intermittent injections of the 1% solution or, more easily, by continuous intravenous drip of a 0.2% solution. Intermittent injections of about 20 to 40 mg (2 to 4 mL of a 1% solution) may be given as required, usually every 4 to 7 minutes. For continuous drip, the average rate of administration is about 3 mL of a 0.2% solution/minute (1 drop/second). The rate of flow must be individualized for each patient. For longer surgical procedures, gradual reduction in the rate of administration is recommended (see discussion of prolonged administration in WARNINGS). Other parenteral agents, usually narcotic analgesics, are ordinarily employed along with Brevital Sodium during longer procedures.
Brevital Sodium is administered intramuscularly in a 5% concentration and administered rectally as a 1% solution.
For the induction of anesthesia by the intramuscular route of administration, the usual dose ranges from 6.6 to 10 mg/kg of the 5% concentration. For rectal administration, the usual dose for induction is 25 mg/kg using the 1% solution.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Solutions of Brevital Sodium should not be mixed in the same syringe or administered simultaneously during intravenous infusion through the same needle with acid solutions, such as atropine sulfate, metocurine iodide, and succinylcholine chloride. Alteration of pH may cause free barbituric acid to be precipitated. Solubility of the soluble sodium salts of barbiturates, including Brevital Sodium, is maintained only at a relatively high (basic) pH.
Because of numerous requests from anesthesiologists for information regarding the chemical compatibility of these mixtures, the following chart contains information obtained from compatibility studies in which a 1% solution of Brevital Sodium was mixed with therapeutic amounts of agents whose solutions have a low (acid) pH.
| Active Ingredient | Potency per mL | Volume Used | Immediate | 15 min | Physical Change 30 min | 1 h |
|---|---|---|---|---|---|---|
| Brevital Sodium | 10 mg | 10 mL | CONTROL | |||
| Atropine Sulfate | 1/150 gr | 1 mL | None | Haze | ||
| Atropine Sulfate | 1/100 gr | 1 mL | None | Ppt | Ppt | |
| Succinylcholine chloride | 0.5 mg | 4 mL | None | None | Haze | |
| Succinylcholine chloride | 1 mg | 4 mL | None | None | Haze | |
| Metocurine Iodide | 0.5 mg | 4 mL | None | None | Ppt | |
| Metocurine Iodide | 1 mg | 4 mL | None | None | Ppt | |
| Scopolamine hydrobromide | 1/120 gr | 1 mL | None | None | None | Haze |
| Tubocurarine chloride | 3 mg | 4 mL | None | Haze |
Store at controlled room temperature (20° to 25°C) (68° to 77°F) [see USP].
Brevital® Sodium Vials1:
500 mg (with 30 mg anhydrous sodium carbonate) are available as follows:
The 2.5 g vials (with 150 mg anhydrous sodium carbonate) are available as follows:
Rx Only.
Prescribing Information as of January 2009.
JHP Pharmaceuticals
Manufactured and Distributed by:
JHP Pharmaceuticals, LLC.
Rochester, MI 48307
3003014B
NDC 42023-105-01
BREVITAL®
SODIUM
CIV
Methohexital Sodium
For Injection, USP
500 mg
ANESTHETIC BARBITURATE
MULTIPLE DOSE VIAL
Rx only
JHP
PHARMACEUTICALS
NDC 42023-105-01
BREVITAL®
SODIUM
CIV
Methohexital Sodium
For Injection, USP
500 mg
ANESTHETIC BARBITURATE
MULTIPLE DOSE VIAL
Rx only
Do not administer without reading
directions in accompanying literature.
JHP
PHARMACEUTICALS
NDC 42023-106-01
BREVITAL®
SODIUM
CIV
Methohexital Sodium
For Injection, USP
2.5 g
ANESTHETIC BARBITURATE
Rx only
JHP
PHARMACEUTICALS
NDC 42023-106-01
BREVITAL®
SODIUM
CIV
Methohexital Sodium
For Injection, USP
2.5 g
ANESTHETIC BARBITURATE
MULTIPLE DOSE VIAL
Rx only
Do not administer without reading
directions in accompanying literature.
JHP
PHARMACEUTICALS
| Brevital Sodium methohexital sodium injection, powder, lyophilized, for solution | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| NDA | NDA011559 | 11/01/2007 | |
| Brevital Sodium methohexital sodium injection, powder, lyophilized, for solution | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| NDA | NDA011559 | 11/01/2007 | |
| Labeler - JHP Pharmaceuticals LLC (804894611) |
SRM-Rhotard may be available in the countries listed below.
Morphine sulphate pentahydrate (a derivative of Morphine) is reported as an ingredient of SRM-Rhotard in the following countries:
International Drug Name Search
Neo-Pyrazon may be available in the countries listed below.
Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Neo-Pyrazon in the following countries:
International Drug Name Search
Fortimicin may be available in the countries listed below.
Astromicin sulfate (a derivative of Astromicin) is reported as an ingredient of Fortimicin in the following countries:
International Drug Name Search
M09AA01
0000522-66-7
C20-H26-N2-O2
326
Antiprotozoal agent: Antimalarial
Muscle relaxant
Dermatological agent: Demelanizing
(-)-4-[Hydroxy-(5-ethyl-2-chinuclidinyl)-methyl]-6-methoxychinolin
International Drug Name Search
Glossary
| IS | Inofficial Synonym |
In the US, Visudyne (verteporfin systemic) is a member of the drug class miscellaneous antineoplastics and is used to treat Macular Degeneration.
US matches:
UK matches:
Verteporfin is reported as an ingredient of Visudyne in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Generic Name: aluminum carbonate (ah LOO mih num CAR boe nate)
Brand Names: Basaljel
Aluminum is a naturally occurring substance. Aluminum carbonate is the carbonate salt form of aluminum designed for oral ingestion.
Aluminum carbonate is used to treat the symptoms of increased stomach acid in conditions such as heartburn, acid reflux, acid indigestion, sour stomach, and stomach ulcers. Aluminum carbonate is also used to treat, control, or manage high levels of phosphate in the body. Aluminum carbonate is also used with a low phosphate diet to prevent the formation of phosphate urinary stones.
Aluminum carbonate may also be used for purposes other than those listed in this medication guide.
Before taking aluminum carbonate, talk to your doctor if you take any other medicines. Aluminum can decrease the effects of many other medicines by binding to them or by changing the acidity of the stomach or the urine.
Before taking this medication, tell your doctor if you
have any condition that causes slow emptying of the stomach; or
take any other medicines.
You may not be able to take aluminum carbonate or you may require a dosage adjustment or special monitoring during treatment if you have any of the conditions listed above.
Take aluminum carbonate exactly as directed by your doctor or on the package. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.
Take the missed dose as soon as you remember. However, if it is almost time for the next dose, skip the dose you missed and take only the next regularly scheduled dose. Do not take a double dose of this medication unless otherwise directed by your doctor.
Symptoms of an aluminum overdose include weight loss, decreased appetite, general feeling of sickness, muscle weakness, kidney failure, and softening of the bones.
Other, less serious side effects may be more likely to occur. Continue to take aluminum and talk to your doctor if you experience constipation. Increased fluid intake may lessen constipation.
Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.
Before taking aluminum carbonate, talk to your doctor if you take any other medicines. Aluminum can decrease the effects of many other medicines by binding to them or by changing the acidity of the stomach or the urine.
Drugs other than those listed here can also interact with aluminum carbonate. Talk to your doctor and pharmacist before taking any over-the-counter or prescription medicines.
Crede Mintic Eximec may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Ivermectin is reported as an ingredient of Crede Mintic Eximec in the following countries:
International Drug Name Search
Ultrasporine may be available in the countries listed below.
Cefalexin is reported as an ingredient of Ultrasporine in the following countries:
International Drug Name Search
Clinda Lich may be available in the countries listed below.
Clindamycin palmitate hydrochloride (a derivative of Clindamycin) is reported as an ingredient of Clinda Lich in the following countries:
International Drug Name Search
Omeprazol Merck may be available in the countries listed below.
Omeprazole is reported as an ingredient of Omeprazol Merck in the following countries:
International Drug Name Search
Sicorten may be available in the countries listed below.
Halometasone monohydrate (a derivative of Halometasone) is reported as an ingredient of Sicorten in the following countries:
International Drug Name Search
Definition of Diabetes Insipidus: Diabetes insipidus is caused by the inability of the kidneys to conserve water, which leads to frequent urination and pronounced thirst.
The following drugs and medications are in some way related to, or used in the treatment of Diabetes Insipidus. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Micromedex Care Notes:
Medical Encyclopedia:
Iwazac may be available in the countries listed below.
Bendazac is reported as an ingredient of Iwazac in the following countries:
International Drug Name Search
Cinchocaïne may be available in the countries listed below.
Cinchocaïne (DCF) is also known as Cinchocaine (Rec.INN)
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
